Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haloperidol + midazolam
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutica
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
A combination medication consisting of haloperidol (a high-potency first-generation antipsychotic) and midazolam (a short-acting benzodiazepine). This combination is primarily used in palliative care and emergency settings for the management of agitation, delirium, and other distressing symptoms. The combination provides more effective and faster control of agitation than haloperidol alone, with a median time to control of 15 minutes versus 60 minutes for haloperidol monotherapy.
02
Targets
DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADRA1A (α1A)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)BZD site (GABA-A receptor benzodiazepine site)
Beyond the preview
Go deeper on haloperidol + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haloperidol + midazolam.